Even in the 2020 RATE-AF trial, despite no obvious improvement in QOL, there were significantly fewer adverse effects and lower pro-B-type natriuretic peptide (BNP) with digoxin therapy in the long term [8-15]. The gene discussed is NPPB; the disease is atrial fibrillation.